Selectively targeting estrogen receptors for cancer treatment

Area of Science:

• Endocrinology
• Molecular Biology
• Oncology

Background:

• Estrogens, acting via estrogen receptors (ERs) ERα and ERβ, control cell proliferation and differentiation.
• Estrogen receptor alpha (ERα) signaling has been a primary target for breast cancer therapy, notably with tamoxifen (a selective estrogen receptor modulator).
• Current therapeutic strategies emphasize tissue selectivity, but receptor subtype selectivity is gaining importance.

Purpose of the Study:

• To review the mechanistic and structural features of ERα and ERβ that dictate tissue and subtype selectivity.
• To highlight current therapeutic strategies for selectively targeting ERα and ERβ in cancer treatment.
• To explore novel approaches for targeting ERα beyond ligand-dependent activity and leveraging ERβ's anti-proliferative role.

Main Methods:

• Review of existing literature on estrogen receptor mechanisms and structures.
• Analysis of current therapeutic approaches targeting ERα and ERβ.
• Discussion of emerging strategies for selective ER targeting.

Main Results:

• Estrogen receptors ERα and ERβ exhibit distinct mechanistic and structural properties influencing selectivity.
• Selective estrogen receptor modulators (SERMs) primarily focus on tissue selectivity for ERα targeting.
• Emerging research explores targeting ERα beyond ligand activity and exploiting ERβ's anti-proliferative effects for cancer therapy.

Conclusions:

• Understanding ER subtype and tissue selectivity is crucial for developing effective cancer therapies.
• Selective targeting of ERα and ERβ offers promising avenues for novel cancer treatments.
• Future research should focus on developing subtype-selective ligands and innovative targeting strategies for both ERα and ERβ.